Katherine

As­traZeneca’s an­ti-IL-33 mon­o­clon­al an­ti­body failed a Phase 2a study in chron­ic ob­struc­tive pul­monary dis­ease, though the com­pa­ny not­ed there were still “en­cour­ag­ing clin­i­cal ef­fi­ca­cy sig­nals

Plus, news on Antabio’s €25 mil­lion Se­ries B, Athi­ra’s Alzheimer’s da­ta, Con­nect’s asth­ma re­sults and Liq­uidia’s $25 mil­lion raise. Almi­rall, eth­er­na’s new part­ner­ship: The com­pa­nies